These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 36494591

  • 1. Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions.
    Devine JK, Schwartz L, Hursh S, Asin J, de Vries N, Vonk PE, Vermeeren A, Donjacour CEHM, Vinckenbosch F, Ramaekers JG, Janssen H, Wang G, Chen D, Carter LP, Overeem S, Lammers GJ.
    Neurol Ther; 2023 Feb; 12(1):249-265. PubMed ID: 36494591
    [Abstract] [Full Text] [Related]

  • 2. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy.
    Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A.
    J Clin Sleep Med; 2022 Jan 01; 18(1):235-244. PubMed ID: 34283019
    [Abstract] [Full Text] [Related]

  • 3. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
    Weaver TE, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Bron M, Chandler P, Lee L, Malhotra A.
    J Clin Sleep Med; 2021 Oct 01; 17(10):1995-2007. PubMed ID: 34606437
    [Abstract] [Full Text] [Related]

  • 4. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea.
    Rosenberg R, Baladi M, Bron M.
    J Clin Sleep Med; 2021 Apr 01; 17(4):711-717. PubMed ID: 33226332
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea.
    Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R.
    Sleep; 2020 Feb 13; 43(2):. PubMed ID: 31691827
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Solriamfetol for the Management of Excessive Daytime Sleepiness.
    Cuomo MC, Sheehan AH, Jordan JK.
    J Pharm Pract; 2022 Dec 13; 35(6):963-970. PubMed ID: 33882756
    [Abstract] [Full Text] [Related]

  • 9. Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy.
    Emsellem HA, Thorpy MJ, Lammers GJ, Shapiro CM, Mayer G, Plazzi G, Chen D, Carter LP, Villa KF, Lee L, Menno D, Black J, Dauvilliers Y.
    Sleep Med; 2020 Mar 13; 67():128-136. PubMed ID: 31926465
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC.
    Nat Sci Sleep; 2021 Mar 13; 13():75-91. PubMed ID: 33531850
    [Abstract] [Full Text] [Related]

  • 12. Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.
    Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K, Lee L, Bujanover S, Strohl KP.
    J Psychiatr Res; 2022 Nov 13; 155():202-210. PubMed ID: 36070638
    [Abstract] [Full Text] [Related]

  • 13. Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.
    Vinckenbosch F, Asin J, de Vries N, Vonk PE, Donjacour CEHM, Lammers GJ, Overeem S, Janssen H, Wang G, Chen D, Carter LP, Zhou K, Vermeeren A, Ramaekers JG.
    Hum Psychopharmacol; 2022 Nov 13; 37(6):e2845. PubMed ID: 35633275
    [Abstract] [Full Text] [Related]

  • 14. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
    Schweitzer PK, Mayer G, Rosenberg R, Malhotra A, Zammit GK, Gotfried M, Chandler P, Baladi M, Strohl KP.
    Chest; 2021 Jul 13; 160(1):307-318. PubMed ID: 33631141
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials.
    Wang J, Yang S, Li X, Wang T, Xu Z, Xu X, Gao H, Chen G.
    Sleep Med; 2021 Mar 13; 79():40-47. PubMed ID: 33472129
    [Abstract] [Full Text] [Related]

  • 17. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy.
    Schweitzer PK, Strohl KP, Mayer G, Rosenberg R, Chandler P, Baladi M, Lee L, Malhotra A.
    J Clin Sleep Med; 2021 Apr 01; 17(4):659-668. PubMed ID: 33179591
    [Abstract] [Full Text] [Related]

  • 18. Solriamfetol for the Treatment of Excessive Sleepiness in OSA: A Placebo-Controlled Randomized Withdrawal Study.
    Strollo PJ, Hedner J, Collop N, Lorch DG, Chen D, Carter LP, Lu Y, Lee L, Black J, Pépin JL, Redline S, Tones 4 Study Investigators.
    Chest; 2019 Feb 01; 155(2):364-374. PubMed ID: 30471270
    [Abstract] [Full Text] [Related]

  • 19. Indirect treatment comparison of solriamfetol, modafinil, and armodafinil for excessive daytime sleepiness in obstructive sleep apnea.
    Ronnebaum S, Bron M, Patel D, Menno D, Bujanover S, Kratochvil D, Lucas E, Stepnowsky C.
    J Clin Sleep Med; 2021 Dec 01; 17(12):2543-2555. PubMed ID: 34402784
    [Abstract] [Full Text] [Related]

  • 20. Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy.
    Malhotra A, Strollo PJ, Pepin JL, Schweitzer P, Lammers GJ, Hedner J, Redline S, Chen D, Chandler P, Bujanover S, Strohl K.
    Sleep Med; 2022 Dec 01; 100():165-173. PubMed ID: 36084494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.